Cerebral Therapeutics is a clinical-stage company dedicated to improving the lives of patients living with severe refractory epilepsy and other uncontrolled neurological diseases. Founded by experts in the fields of neurology, neurosurgery, and drug delivery, the Company is pioneering the development of drug-device combination therapies that enable precise targeted delivery to the central nervous system. The goal of this novel approach is to maximize efficacy while greatly reducing systemic drug exposure and enhancing drug regimen compliance. Cerebral Therapeutics' intracerebroventricular (ICV) infusion therapy may offer a more efficacious and reliable approach to treating neurological diseases for which oral medications are not able to achieve adequate control and/or are limited by systemic toxicities.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/07/20 | $35,000,000 | Series B |
Granite Point Capital Management RA Capital Management  Vivo Capital | undisclosed |
| 06/28/22 | $40,000,000 | Series C |
Granite Point Capital Management Lynx1 Capital Management Perceptive Advisors RA Capital Management Vivo Capital | undisclosed |
